Plasma Neuroendocrine Markers in Patients with Benign Prostatic Hyperplasia and Prostatic Carcinoma
The Journal of Urology, ISSN: 0022-5347, Vol: 155, Issue: 4, Page: 1340-1343
1996
- 100Citations
- 19Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Approximately 50 percent of all malignant prostatic tumors contain neuroendocrine cells, which cannot be attributed to small cell prostatic carcinoma or carcinoid-like tumors, and which represent only 1 to 2 percent of all prostatic malignancies. Only limited data are available concerning the plasma levels of neuroendocrine markers in patients with prostatic tumors. Therefore, we determined the incidence of high plasma levels of neuroendocrine markers in patients with benign and malignant prostatic disease.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S002253470166261X; http://dx.doi.org/10.1016/s0022-5347(01)66261-x; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=9044235581&origin=inward; http://linkinghub.elsevier.com/retrieve/pii/S002253470166261X; http://api.elsevier.com/content/article/PII:S002253470166261X?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S002253470166261X?httpAccept=text/plain; http://www.jurology.com/doi/10.1016/S0022-5347%2801%2966261-X; http://dx.doi.org/10.1016/s0022-5347%2801%2966261-x; https://dx.doi.org/10.1016/s0022-5347%2801%2966261-x; https://www.auajournals.org/doi/10.1016/S0022-5347%2801%2966261-X
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know